Novel Treatments for Chronic Viral Infections
ContraVir seeks to develop and commercialize novel drug treatments to improve the lives of patients suffering from chronic viral infections, with an initial focus on herpes zoster, or shingles, and hepatitis B.
A Novel Drug Candidate for Hepatitis B
CMX157 has completed a Phase 1 clinical trial in healthy volunteers, demonstrating a favorable safety, tolerability and drug distribution profile. ContraVir intends to develop CMX157 for Hepatitis B (HBV).
A Shingles Treatment with Best in Class Potential
Our lead candidate is FV-100, a potent oral antiviral being developed for the treatment of herpes zoster, commonly known as shingles. FV-100 is well-tolerated and has been shown to reduce PHN pain in Phase 2 trials.
ContraVir is developing targeted antiviral therapies with two drug candidates in clinical studies. FV-100, now in Phase 3 trials, is being developed for the treatment of herpes zoster, or shingles, and shingle pain. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®).
CMX157 is a novel, highly potent lipid conjugate of the successful antiviral drug tenofovir, marketed by Gilead as Viread®. CMX157 has completed a Phase 1 clinical trial in healthy volunteers with positive initial results. ContraVir intends to develop CMX157 for Hepatitis B in Phase 2 clinical studies.
- Preliminary evaluation of safety and pharmacokinetics in Phase 1 complete
- Safe and well-tolerated
- Potential to improve safety (reduced plasma exposure to tenofovir) compared to Viread®
- Potential to improve efficacy (increased active tenofovir in target cells) compared to Viread®
We are developing FV-100 as a fast-acting, low-dose, once-daily, oral antiviral therapy for the treatment of herpes zoster, or shingles, an infection caused by the reactivation of the varicella zoster (chicken pox) virus. In addition to its potent antiviral activity, FV-100 has demonstrated an ability to reduce shingles-associated pain, known as post-herpetic neuralgia, or PHN.
- Initiating Phase 3 clinical study
- Well-tolerated with demonstrated reduction in PHN in Phase 2 trials
- Potential for more convenient dosing; no dose adjustment required for patients with renal insufficiency
- Strong IP position